SHANGHAI – Zai Labs Ltd., of Shanghai, signed a China rights deal, including Hong Kong and Macau, for a coveted late-stage targeted non-small-cell lung cancer (NSCLC) therapy, HM61713, from Hanmi Pharmaceuticals Co. Ltd., of Seoul, South Korea.